CXCR4 and breast carcinoma: Concordantly, the syndecan‐2‐peptide‐induced reduction in CXCR4 and PD‐L1 expression in TASCs coincided with an increase in the levels of activated T cells within the TME and a decrease in tumour growth in an immune competent syngeneic breast cancer model.